FI4401833T3 - Gpr52:n muuntajayhdisteitä - Google Patents

Gpr52:n muuntajayhdisteitä

Info

Publication number
FI4401833T3
FI4401833T3 FIEP22778038.4T FI22778038T FI4401833T3 FI 4401833 T3 FI4401833 T3 FI 4401833T3 FI 22778038 T FI22778038 T FI 22778038T FI 4401833 T3 FI4401833 T3 FI 4401833T3
Authority
FI
Finland
Prior art keywords
disorder
disorders
salt
compound
disease
Prior art date
Application number
FIEP22778038.4T
Other languages
English (en)
Finnish (fi)
Inventor
Stephen Paul Watson
Nigel Alan Swain
Michael Alistair O'brien
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Application granted granted Critical
Publication of FI4401833T3 publication Critical patent/FI4401833T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP22778038.4T 2021-09-15 2022-09-15 Gpr52:n muuntajayhdisteitä FI4401833T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2113186.7A GB202113186D0 (en) 2021-09-15 2021-09-15 GPR52 Modulator compounds
PCT/GB2022/052328 WO2023041909A1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
FI4401833T3 true FI4401833T3 (fi) 2025-11-25

Family

ID=78149263

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22778038.4T FI4401833T3 (fi) 2021-09-15 2022-09-15 Gpr52:n muuntajayhdisteitä

Country Status (22)

Country Link
US (1) US20240376070A1 (https=)
EP (1) EP4401833B1 (https=)
JP (1) JP2024535860A (https=)
KR (1) KR20240058852A (https=)
CN (1) CN117999258A (https=)
AU (1) AU2022348201A1 (https=)
CA (1) CA3232606A1 (https=)
CL (1) CL2024000742A1 (https=)
DK (1) DK4401833T3 (https=)
ES (1) ES3053759T3 (https=)
FI (1) FI4401833T3 (https=)
GB (1) GB202113186D0 (https=)
HR (1) HRP20251420T1 (https=)
IL (1) IL311015A (https=)
LT (1) LT4401833T (https=)
MX (1) MX2024003248A (https=)
PL (1) PL4401833T3 (https=)
PT (1) PT4401833T (https=)
RS (1) RS67399B1 (https=)
SI (1) SI4401833T1 (https=)
SM (1) SMT202500449T1 (https=)
WO (1) WO2023041909A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004193A (ko) 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
JP7394747B2 (ja) * 2017-09-13 2023-12-08 ノバルティス アーゲー ジフェニル誘導体及びその使用
CA3156474A1 (en) * 2019-11-08 2021-05-14 Heptares Therapeutics Limited GPR52 MODULATING COMPOUNDS
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds

Also Published As

Publication number Publication date
AU2022348201A1 (en) 2024-03-28
KR20240058852A (ko) 2024-05-07
EP4401833A1 (en) 2024-07-24
LT4401833T (lt) 2025-12-10
WO2023041909A1 (en) 2023-03-23
GB202113186D0 (en) 2021-10-27
JP2024535860A (ja) 2024-10-02
SI4401833T1 (sl) 2026-01-30
EP4401833B1 (en) 2025-10-22
DK4401833T3 (da) 2025-11-17
PT4401833T (pt) 2025-11-14
CN117999258A (zh) 2024-05-07
PL4401833T3 (pl) 2026-02-16
HRP20251420T1 (hr) 2026-01-02
RS67399B1 (sr) 2025-11-28
MX2024003248A (es) 2024-04-02
ES3053759T3 (en) 2026-01-26
CL2024000742A1 (es) 2024-09-27
IL311015A (en) 2024-04-01
US20240376070A1 (en) 2024-11-14
SMT202500449T1 (it) 2026-01-12
CA3232606A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
FI4401833T3 (fi) Gpr52:n muuntajayhdisteitä
Brandel et al. Structural aspects of solid solutions of enantiomers
WO2007066828A1 (ja) 光学活性な4-アミノ-3-置換フェニルブタン酸の製造方法
BRPI0413359A (pt) produção contìnua de pré-formas de recipiente
CN104370791B (zh) 一种左乙拉西坦的纯化方法
SE458118B (sv) Foerfarande foer framstaellning av ett injicerbart kondroitinpolysulfat, en produkt som kan erhaallas genom detta foerfarande och en farmaceutisk komposition
JP2013147506A (ja) イオン性液体の精製方法
Castagnolo et al. Enantioselective carbolithiation of S-alkenyl-N-aryl thiocarbamates: kinetic and thermodynamic control
JP2024535860A5 (https=)
CN102942593B (zh) 一种光引发剂双(2,4,6-三甲基苯甲酰基)苯基氧化膦的合成方法
Pavia et al. Benzo-fused bicyclic imides
RU2024109992A (ru) Соединения-модуляторы gpr52
Basavaiah et al. A study toward understanding the role of a phosphorus stereogenic center in (5S)-1, 3-diaza-2-phospha-2-oxo-3-phenylbicyclo (3.3. 0) octane derivatives as catalysts in the borane-mediated asymmetric reduction of prochiral ketones
JP2017521437A (ja) アピキサバンの製造方法
TWI546312B (zh) 以無溶劑製程製備環磷醯胺之方法
Dyachenko et al. Novel approaches to synthesis of 4-alkyl-6-amino-5-cyano-3-methyl (propyl, phenyl)-2H, 4H-pyrano [2, 3-c] pyrazoles
CN104098529B (zh) 无机金属硫化物促进二硫化碳与邻卤苯胺反应合成2-巯基苯并噻唑的方法
CN108424409A (zh) 一种固体酸催化合成光引发剂2,4-二乙基硫杂蒽酮的方法
TW200745134A (en) One pot synthesis of tetrazole derivatives of sirolimus
CN107793433A (zh) 一种头孢噻啶的制备方法
CN106380462A (zh) 一种环状聚酯低聚物的制备方法
Karaarslan et al. Preparation of heterotricyclic chlorides via intramolecular Diels-Alder reaction of furans
El-Sayed et al. Synthesis of novel trithiocarbonate-S-oxides
AU2014401238A1 (en) Method for separating and purifying p-dichlorobenzene
Beyer et al. Morphology and crystallinity of the two diastereomer racemates of triglycidyl isocyanurate (TGIC)